Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | 3D185 |
Synonyms | |
Therapy Description |
3D185 inhibits FGFR1/2/3 and CSF-1R, which potentially inhibits Fgfr signaling, modulates the tumor microenvironment, and inhibits tumor growth (PMID: 31438996). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
3D185 | 3D-185|3D 185|HH185 | CSF1R Inhibitor 28 FGFR1 Inhibitor 28 FGFR2 Inhibitor 23 FGFR3 Inhibitor 19 | 3D185 inhibits FGFR1/2/3 and CSF-1R, which potentially inhibits Fgfr signaling, modulates the tumor microenvironment, and inhibits tumor growth (PMID: 31438996). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
FGFR3 amp | urinary bladder cancer | sensitive | 3D185 | Preclinical - Cell culture | Actionable | In a preclinical study, 3D185 inhibited proliferation of a bladder cancer cell line harboring FGFR3 amplification in culture (PMID: 31438996). | 31438996 |
FGFR3 S249C | urinary bladder cancer | sensitive | 3D185 | Preclinical - Cell culture | Actionable | In a preclinical study, 3D185 inhibited downstream signaling and proliferation in a bladder cancer cell line harboring FGFR3 S249C in culture (PMID: 31438996). | 31438996 |
FGFR2 amp | stomach cancer | sensitive | 3D185 | Preclinical - Cell line xenograft | Actionable | In a preclinical study, 3D185 inhibited downstream signaling and proliferation of gastric cancer cell lines harboring FGFR2 amplification in culture and induced dose-dependent tumor growth inhibition in a cell line xenograft model (PMID: 31438996). | 31438996 |
FGFR2 amp | triple-receptor negative breast cancer | sensitive | 3D185 | Preclinical - Cell culture | Actionable | In a preclinical study, 3D185 inhibited proliferation of a triple-negative breast cancer cell line harboring FGFR2 amplification in culture (PMID: 31438996). | 31438996 |
FGFR3 fusion FGFR3 mut | multiple myeloma | sensitive | 3D185 | Preclinical - Cell culture | Actionable | In a preclinical study, 3D185 inhibited proliferation of a multiple myeloma cell line harboring an FGFR3 fusion and an FGFR3 mutation in culture (PMID: 31438996). | 31438996 |
FGFR1 amp | lung cancer | sensitive | 3D185 | Preclinical - Cell line xenograft | Actionable | In a preclinical study, 3D185 inhibited downstream signaling and proliferation of a lung cancer cell line harboring FGFR1 amplification in culture and inhibited signaling and induced dose-dependent tumor growth inhibition in a cell line xenograft model (PMID: 31438996). | 31438996 |
FGFR1 V561M | Advanced Solid Tumor | predicted - sensitive | 3D185 | Preclinical - Biochemical | Actionable | In a preclinical study, 3D185 inhibited kinase activity of FGFR1 V561M in an in vitro assay (PMID: 31438996). | 31438996 |
FGFR2 amp | colorectal cancer | sensitive | 3D185 | Preclinical - Cell culture | Actionable | In a preclinical study, 3D185 inhibited proliferation of a colorectal cancer cell line harboring FGFR2 amplification in culture (PMID: 31438996). | 31438996 |
FGFR2 N549H | Advanced Solid Tumor | predicted - sensitive | 3D185 | Preclinical - Biochemical | Actionable | In a preclinical study, 3D185 inhibited the kinase activity of FGFR2 N549H in an in vitro assay (PMID: 31438996). | 31438996 |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|